Experience of using double bronchodilation therapy in patients with COPD
https://doi.org/10.21518/2079-701X-2020-21-90-95
Abstract
Chronic obstructive pulmonary disease (COPD) is currently one of the most socially significant diseases that leads to a significant decrease in the daily activity and productivity of patients, as well as their rapid invalidization. In this regard, its treatment remains the most important problem of medicine. Currently, the main goals of treatment of patients with COPD are: relief of symptoms, improvement of exercise tolerance, improvement of General health, prevention and effective treatment of complications, prevention and effective treatment of exacerbations, prevention of disease progression, and reduction of mortality. The article presents a clinical case from the practice of a patient with COPD who received olodaterol + Tiotropium bromide. In view of the patient’s low adherence to therapy, further progression of the disease was observed, which led to a significant violation of airway patency during spirometry, and a decrease in exercise tolerance. The patient was assigned a new representative of combined drugs with 24-hour action - Vilanterol + Umeclidinium 22/55 mcg, with a new method of drug delivery. After 6 months of therapy with Vilanterol + Umeclidinium, the patient’s exercise tolerance increased, lung function improved, and quality of life improved.
About the Authors
I. V. Demko
Krasnoyarsk State Medical University named after Professor V.F. Voino-Yasenetsky;
Regional Clinical Hospital
Russian Federation
Russian Federation
Dr. of Sci. (Med.), Professor, Head of Department of hospital therapy and Immunology with Postgraduate Education Course, 1, Partizan Zheleznyak St., Krasnoyarsk, 660022;
Head of Pulmonary Allergology Сenter, 3, Partizan Zheleznyak St., Krasnoyarsk, 660022
N. V. Gordeeva
Krasnoyarsk State Medical University named after Professor V.F. Voino-Yasenetsky;
Regional Clinical Hospital
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Associate Professor of Department of hospital therapy and Immunology with Postgraduate Education Course, 1, Partizan Zheleznyak St., Krasnoyarsk, 660022;
Pulmonologist, 3, Partizan Zheleznyak St., Krasnoyarsk, 660022
A. Yu. Kraposhina
Krasnoyarsk State Medical University named after Professor V.F. Voino-Yasenetsky;
Regional Clinical Hospital
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Associate Professor of Department of hospital therapy and Immunology with Postgraduate Education Course, 1, Partizan Zheleznyak St., Krasnoyarsk;
Pulmonologist, 3, Partizan Zheleznyak St., Krasnoyarsk, 660022
M. G. Mamaeva
Krasnoyarsk State Medical University named after Professor V.F. Voino-Yasenetsky;
Regional Clinical Hospital
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Assistant of Department of hospital therapy and Immunology with Postgraduate Education Course, 1, Partizan Zheleznyak St., Krasnoyarsk, 660022;
Pulmonologist, 3, Partizan Zheleznyak St., Krasnoyarsk, 660022
I. A. Soloveva
Krasnoyarsk State Medical University named after Professor V.F. Voino-Yasenetsky;
Regional Clinical Hospital
Russian Federation
Russian Federation
Dr. of Sci. (Med.), Vice-rector for academic Affairs, Associate Professor of Department of hospital therapy and Immunology with Postgraduate Education Course, 1, Partizan Zheleznyak St., Krasnoyarsk, 660022;
Pulmonologist, 3, Partizan Zheleznyak St., Krasnoyarsk, 660022
References
1. Kulik E.G., Pavlenko V.I., Naryshkina S.V. The probabilistic assessment of exacerbations in patients with copd of low risk category on the background of prolonged treatment with roflumilast. Amurskiy meditsinskiy zhurnal = Amur Medical Journal. 2019;(3):19–22. (In Russ.) Available at: https://elibrary.ru/item.asp?id=41440324.
2. Zyryanov S.K., Galatonova Y.A. Clinical and economic evaluation of using fixed dose dual bronchodilator combination tiotropiumolodaterol in patients with chronic obstructive pulmonary disease. Meditsinskiy sovet = Medical Council. 2018;(6):61-65. (In Russ.) doi: 10.21518/2079-701X-2018-6-61-65.
3. Chuchalin A.G., Khaltaev N., Antonov N.S., Galkin B.V., Manakov L.G., Antonini P. et al. Chronic respiratory pulmonary diseases and risk factors in 12 regions of the Russian Federation. Int J COPD. 2014;9(1):963–974. doi: 10.2147/COPD.S67283.
4. Demko I.V., Mamayeva M.G., Gordeyeva N.V., Solovyeva I.A., Kraposhina A. Yu. Clinical experience of using double bronchodilation therapy in patients with COPD. Meditsinskiy sovet = Medical Council. 2019;(15):7–10. (In Russ.) doi: 10.21518/2079-701X-2019-15-7-10
5. Romanovskikh Anna G., Belotserkovskaya Yu.G., Sturt E.A. Modern approaches to pharmacotherapy of chronic obstructive pulmonary disease: the role of fixed combined medications. Klinicheskaya meditsina = Clinical Medicin (Russian Jornal). 2015;93(12):38–43. (In Russ.) Available at: https://elibrary.ru/item.asp?id=25401657.
6. Avdeev S.N., Aisanov Z.R., Belevskiy A.S., Vizel A.A., Zyryanov S.K., Ignatova G.L. et al. New opportunities for prevention of exacerbations of chronic obstructive pulmonary disease. Russian Respiratory Society Expert Opinion. Pulmonologiya = Pulmonologiya. 2017;27(1):108–113. (In Russ.) doi: 10.18093/0869-0189-2017-27-1-108-113.
7. Sinopalnikov A.I. Fixed-dose combinations of bronchodilators in the treatment of patients with COPD: problem of choice. Meditsinskiy sovet = Medical Council. 2018;(15):96–100. (In Russ.) doi: 10.21518/2079-701X2018-15-96-100.
8. Riley C.M., Sciurba F.C. Diagnosis and Outpatient Management of Chronic Obstructive Pulmonary Disease: A Review. JAMA. 2019;321(8):786–797. doi: 10.1001/jama.2019.0131.
9. Leshchenko I.V. Fixed dose long-acting bronchodilator combinations in chronic obstructive pulmonary disease: safety, effectiveness and cardiovascular system. Meditsinskiy sovet = Medical Council. 2018;(15):18–26. (In Russ.) doi: 10.21518/2079-701X-2018-15-18-26.
10. Calzetta L., Matera, M.G., Cazzola M. Pharmacological interaction between LABAs and LAMAs in the respiratory tract: optimization of synergy. Eur J Pharmacol. 2015;(761):168–173. doi: 10.1016/j.ejphar.2015.05.020.
11. Ferguson G.T., Flezar M., Korn S., Korducki L., Grönke L., Abrahams R., Buhl R. Efficacy of tio tropium+olodaterol in patients with chronic obstructive pul monary disease by initial disease severity and treatment inten sity: a post hoc analysis. Adv Ther. 2015;32(6):523–536. doi: 10.1007/s12325-015-0218-0.
12. Beeh K.M., Westerman J., Kirsten A.M., Hébert J., Grönke L., Hamilton A. et al. The 24h lung function profile of once daily tiotropium and olodaterol fixed dose combination in chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2015;(32):53–59. doi: 10.1016/j.pupt.2015.04.002.
13. Ignatova G.L., Antonov V.N. Nebulizer therapy for lung diseases. Meditsinskiy sovet = Medical Council. 2020;(11):102-106. (In Russ.) doi: 10.21518/2079-701X-2020-11-102-106.
14. Cazzola M., Molimard M. The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010;23(4):257–267. doi: 10.1016/j.pupt.2010.03.003.
15. Vizel A.A., Vizel I.Y., Bakunina E.A. Chronic obstructive pulmonary disease. modern approaches to therapy. Meditsinskiy sovet = Medical Council. 2016;(15):6–10. (In Russ.) doi: 10.21518/2079-701X-2016-15-6-10.
16. Calzetta L., Rogliani P., Matera M.G., Cazzola M. A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. Сhest. 2016;149(5):1181–1196. doi: 10.1016/j.chest.2016.02.646.
17. Donohue J.F., Maleki-Yazdi M.R., Kilbride S, Mehta R., Kalberg C., Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107(10):1538–1546. doi: 10.1016/j.rmed.2013.06.001.
18. Avdeev S.N., Aysanov Z.R., Belevsky A.S. Сlinical guidelines of Russian respiratory society: algorithm for the management of patients with COPD. Terapiya = Therapy. 2017;(4):102–106. (In Russ.) Available at: https://therapy-journal.ru/ru/archive/article/35046.
19. Sviderskay L.N., Simakova V.M., Demko I.V., Khendogina V.T., Kudryavtseva A.N., Tretyak T.S. et al. Comparative analysis of organising the control at availability and quality of health care in regional consultative polyclinic. Sibirskoe meditsinskoe obozrenie = Siberian Medical Review. 2016;(5):53–64. (In Russ.) Available at: https://elibrary.ru/item.asp?id=27487911.
20. Singh D., Ferguson G.T., Bolitschek J., Grönke L., Hallmann C., Bennett N. et al. Tiotropium + olodaterol shows clinically meaningful improvements in qual ity of life. Respir Med. 2015;109(10):1312–1319. doi: 10.1016/j.rmed.2015.08.002.
21. Trushenko N.V., Sopova M.I., Sopova V.I. Chronic obstructive pulmonary disease phenotypes – the way to personalized therapy. Prakticheskaya pulmonologiya = Practical Pulmonology. 2019;(3):32–39. (In Russ.) Available at: https://elibrary.ru/item.asp?id=42211538.
22. Blair H.A., Deeks E.D. Umeclidinium/vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary disease. Drugs. 2015;75(1):61–74. doi: 10.1007/s40265-014-0326-1.
23. Feldman G.J., Sousa A.R., Lipson D.A., Tombs L., Barnes N., Riley J.H. et al. Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study. Adv Ther. 2017;34(1):2518–2533. doi: 10.1007/s12325-017-0626-4.
24. Calzetta L., Matera M.G., Cazzola M., Rogliani P. Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients. Adv Ther. 2019;36(12):3291–3298. doi: 10.1007/s12325-019-01119-w.
25. Tolkushin A. G., Pogudin N. L. Pharmacoeconomic Analysis of Drug Therapy of Chronic Obstructive Pulmonary Disease: Umeclidinium Bromide/Vilanterol Compared with other Combinations of Long-Acting β-Antagonists and Anticholinergics. Meditsinskie tekhnologii. Otsenka i vybor = Medical Technologies. Assessment and Choice. 2018;(3):75–88. (In Russ.) doi: 10.31556/2219-0678.2018.33.3.075-088.
26. Zykov K.A., Ovcharenko S.I. Approaches to drug therapy in patients with stable COPD: suggested treatment algorithm. Meditsinskiy sovet = Medical Council. 2015;(17):24-31. (In Russ.) doi: 10.21518/2079-701X2015-17-24-31.
27. Avdeev S.N., Aisanov Z.R. Maximal bronchodilation with starting therapy of chronic obstructive pulmonary disease: an influence on the course of the disease. Pulmonologiya = Russian Pulmonology. 2016;26(5):604–609. (In Russ.) doi: 10.18093/0869-0189-2016-26-5-604-609.
Review
For citations:
Demko IV, Gordeeva NV, Kraposhina AY, Mamaeva MG, Soloveva IA. Experience of using double bronchodilation therapy in patients with COPD. Meditsinskiy sovet = Medical Council. 2020;(21):90-95. (In Russ.) https://doi.org/10.21518/2079-701X-2020-21-90-95
Views:
604
Email this article 